Transitional cell carcinoma clinical study (dogs).
- Overland Park, KS
- Southfield, MI
BluePearl pet hospitals in Overland Park and Southfield are participating in a fully-funded study evaluating the safety and preliminary pain management and potential anti-cancer effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).
NOTE: Anti-cancer therapies must be discontinued 21 days prior to enrollment. Medications targeted at the treatment of TCC-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.
For eligibility, dogs must meet the criteria below.
- A diagnosis of TCC exclusively associated with the bladder or bladder and prostate (no urethral involvement). Metastasis is acceptable.
- Accompanying lower urinary tract clinical signs associated with bladder cancer.
- Bladder lesion does not prevent the passage of urinary catheter.
- Does not have any underlying disease that will affect the study objectives or patient safety.
- Does not have evidence of hydronephrosis.
- Does not have an active urinary tract infection (dogs presenting for screening will have a urine culture performed prior to enrollment).
- Does not have a urethral obstruction.
- Is not pregnant or lactating.
- Is not participating in another study.
Kansas – Overland Park participation.
Contact Dr. Heather Heeb, Adrienne Hagar, or Beth Rogers at (913) 642-9563.
Michigan – Southfield participation.
Contact Dr. Angela Kozicki or Ashley Davis at (248) 354-6640.
Utah – Midvale participation.
Contact Dr. Katherine Wright or Ashley Harmon-Neilson at (801) 871-0600.